These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26709892)

  • 1. An update on the pathology of neuroendocrine tumors.
    Guadagno E; De Caro Mdel B; Insabato L
    Front Biosci (Schol Ed); 2016 Jan; 8(1):1-12. PubMed ID: 26709892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neuroendocrine tumors of digestive system: morphologic spectrum and cell proliferation (Ki67 index)].
    Delektorskaia VV; Kushliskiĭ NE
    Vestn Ross Akad Med Nauk; 2013; (5):28-37. PubMed ID: 24000665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathology of NET: Current concepts and new developments.
    Schmitt AM; Blank A; Marinoni I; Komminoth P; Perren A
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):33-43. PubMed ID: 26971842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask.
    Albertelli M; Grillo F; Lo Calzo F; Puliani G; Rainone C; Colao AAL; Faggiano A;
    Front Endocrinol (Lausanne); 2021; 12():680305. PubMed ID: 33967966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastric neuroendocrine neoplasms and related precursor lesions.
    La Rosa S; Vanoli A
    J Clin Pathol; 2014 Nov; 67(11):938-48. PubMed ID: 25053544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interpretation on the update of 2022 WHO classification of neuroendocrine tumors].
    Mao XX; Chen J
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):655-659. PubMed ID: 38955694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?
    Pelosi G; Fabbri A; Cossa M; Sonzogni A; Valeri B; Righi L; Papotti M
    Semin Diagn Pathol; 2015 Nov; 32(6):469-79. PubMed ID: 26561395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors.
    Kim D; Viswanathan K; Goyal A; Rao R
    Cancer Cytopathol; 2020 Apr; 128(4):269-277. PubMed ID: 31977134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic endocrine tumors.
    Asa SL
    Mod Pathol; 2011 Apr; 24 Suppl 2():S66-77. PubMed ID: 21455203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is a neuroendocrine tumor?
    Yesner R
    Am J Surg Pathol; 2000 Feb; 24(2):319-20. PubMed ID: 10680908
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pathology of neuroendocrine neoplasms].
    Anlauf M; Gerlach P; Schott M; Raffel A; Krausch M; Knoefel WT; Pavel M; Klöppel G
    Chirurg; 2011 Jul; 82(7):567-73. PubMed ID: 21487814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic Neuroendocrine Tumors.
    Salaria SN; Shi C
    Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers.
    Duan K; Mete O
    Cancer Cytopathol; 2016 Dec; 124(12):871-884. PubMed ID: 27529763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology.
    Chetty R
    Arch Pathol Lab Med; 2008 Aug; 132(8):1285-9. PubMed ID: 18684027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Briest F; Wang Y; Arsenic R; Elezkurtaj S; Berg E; Greshake S; Lock AC; Hörsch D; Arnold CN; Hummel M; Siegmund B; Grabowski P
    Anticancer Res; 2018 Jul; 38(7):3863-3870. PubMed ID: 29970506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What is new in the pathology of pancreatic neuroendocrine tumors?].
    Komminoth P; Perren A
    Pathologe; 2015 May; 36(3):220-8. PubMed ID: 25941099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy?
    Koo J; Dhall D
    Semin Diagn Pathol; 2015 Nov; 32(6):456-68. PubMed ID: 26573790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.
    Klimstra DS; Modlin IR; Adsay NV; Chetty R; Deshpande V; Gönen M; Jensen RT; Kidd M; Kulke MH; Lloyd RV; Moran C; Moss SF; Oberg K; O'Toole D; Rindi G; Robert ME; Suster S; Tang LH; Tzen CY; Washington MK; Wiedenmann B; Yao J
    Am J Surg Pathol; 2010 Mar; 34(3):300-13. PubMed ID: 20118772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
    Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
    World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
    Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
    Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.